Replies to post #252927 on The Golden Lounge

[Theo]

And this explains ISIS's move:

Isis Pharmaceuticals Earns $15 Million from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx
Successful collaboration with AstraZeneca includes two novel cancer drugs in clinical development

ISIS news

"CARLSBAD, Calif., June 10, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS) announced today that AstraZeneca has initiated a Phase 1 clinical study of ISIS-ARRx in patients with cancer. Isis earned a $15 million milestone payment associated with the clinical advancement of ISIS-ARRx. ISIS-ARRx is an antisense drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor (AR). AstraZeneca is planning to develop ISIS-ARRx broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy...."